Kathleen N. Moore

University of Southern California — United States

Medicine · Health Sciences

85h-index46.6kcitations1.1kworks3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(491), PARP inhibition in cancer therapy(184), Endometrial and Cervical Cancer Treatments(166), Cancer Immunotherapy and Biomarkers(95), Cervical Cancer and HPV Research(69)

Publications1.1k total

Parameter efficient fine-tunning of foundation model to facilitate tumor response prediction for ovarian cancer patients
BMC Medical Imaging·2025Open Access
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Future Oncology·2025· 1 citedOpen Access
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma
Clinical Cancer Research·2025Open Access
Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2025Open Access
Supplementary Figure S3 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Figure S1 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Figure S2 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025Open Access
Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
2025Open Access
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
Gynecologic Oncology·2025
REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
International Journal of Gynecological Cancer·2025
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
Journal of Clinical Oncology·2025
Abstract C040: Real-world characterization of PTK7, an oncofetal pseudokinase expressed in multiple solid tumors
Molecular Cancer Therapeutics·2025
S3593 Two for One: A Rare Case of Squamous Cell Lung Cancer With Synchronous Pancreatic and Hepatic Metastases
The American Journal of Gastroenterology·2025
S3592 Sweet but Not Innocent: A Case of D-Mannose and Amiodarone-Induced Pancreatitis
The American Journal of Gastroenterology·2025
Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005)
Cancer Research·2025
Abstract A030: 2X-121, a novel, dual inhibitor of PARP and tankyrase, shows promising clinical benefit in a phase 2 trial in advanced, recurrent ovarian cancer patients (NCT#03878849)
Cancer Research·2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation
Gynecologic Oncology·2025· 3 cited
LBA31 Neoadjuvant immunotherapy induces immune activation and responses in MMR-proficient colon cancers
Annals of Oncology·2025Open Access
1101P FIRST/ENGOT-OV44 trial: Does the addition of dostarlimab (dost) impact niraparib (nira) tolerability, exposure, or dose modification?
Annals of Oncology·2025
page 1 of 54Next →

Frequent Co-authors

Nicoletta Colombo(10), David M. O’Malley(10), Ana Oaknin(9), Amit M. Oza(9), Susana Banerjee(8), Carol Aghajanian(8), Ursula A. Matulonis(8), Antonio González-Martı́n(7), Robert L. Coleman(7), Michael A. Bookman(7), Michael J. Birrer(7), Ignace Vergote(7), Giovanni Scambia(6), Bradley J. Monk(6), Alexandra Léary(5), Charlie Gourley(5), Paul DiSilvestro(5), Sandro Pignata(5), Domenica Lorusso(5), Michael Friedländer(4)